Crohn’s disease

Latest

Childhood antibiotic exposure linked to gut microbiome disruption and increased IBD risk

Childhood antibiotic exposure linked to gut microbiome disruption and increased IBD risk

Medical illustration of the digestive tract showing the large intestine highlighted in orange surrounding the small intestine in white, against a black background to illustrate upadacitinib demonstrating one-year effectiveness in refractory perianal Crohn’s disease

Upadacitinib demonstrates one-year effectiveness in refractory perianal Crohn’s disease

Minimalist illustration of a stylized intestine in bright blue

Biosimilars in IBD: key ustekinumab research from ECCO’26

A clinician holding their hands out with a holographic bowel scan projection over the top with vital signs and medical record icons around it to illustrate the 3D imaging of Crohn's disease strictures

3D imaging and Crohn’s disease strictures: practice perspectives

The benefits of transitioning to biosimilar adalimumab in Crohn’s disease

The benefits of transitioning to biosimilar adalimumab in Crohn’s disease

Study redefines early treatment of Crohn’s disease and improves outcomes

Study redefines early treatment of Crohn’s disease and improves outcomes

Risankizumab surpasses ustekinumab when head to head in Crohn‘s disease

Risankizumab surpasses ustekinumab when head to head in Crohn‘s disease

MHRA approves rinvoq for moderate to severe Crohn's disease

MHRA approves upadacitinib for moderate to severe Crohn's disease

Therapeutic drug monitoring of adalimumab in paediatric Crohn's disease

Monitoring adalimumab levels valuable for assessing remission in children with Crohn’s disease